<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676871</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP155</org_study_id>
    <nct_id>NCT00676871</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 In Adults With B-Cell Chronic Lymphocytic Leukemia(CLL)Who Have Residual Disease Following Previous Therapy for CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1:&#xD;
&#xD;
        -  Evaluate the safety and tolerability of MEDI-538 given by escalated doses with&#xD;
           continuous IV infusion for 4 weeks in adult patients with CLL.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of MEDI-538 administered by continuous IV&#xD;
           infusion for 4 weeks in this patient population&#xD;
&#xD;
        -  Describe the pharmacokinetics (PK) of MEDI-538&#xD;
&#xD;
        -  Describe the immunogenicity (IM) of MEDI-538&#xD;
&#xD;
        -  Determine the overall response, which is defined as follows: (1) conversion from PD/SD&#xD;
           to PR/nPR/CR or conversion from PR to nPR/CR using standard NCI-WG criteria; or (2)&#xD;
           conversion from MRD positivity to MRD negativity using 4-color flow cytometry; and&#xD;
&#xD;
        -  Describe any antitumor activity (ie, time to response and duration of response) of&#xD;
           MEDI-538 in this patient population.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
        -  To determine the overall response in adult patients with CLL who have residual disease&#xD;
           following previous therapy for CLL.&#xD;
&#xD;
        -  Describe the safety,PK,and IM of MEDI-538&#xD;
&#xD;
        -  Determine the time to MRD relapse&#xD;
&#xD;
        -  Determine the antitumor activity (ie, time to response, duration of response,and time to&#xD;
           progression [TTP])of MEDI-538 in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1:&#xD;
&#xD;
        -  Evaluate the safety and tolerability of MEDI-538 at doses of 5, 10, 15, 30, 45, or 60&#xD;
           mg/m2/24h by continuous IV infusion for 4 weeks in adult patients with CLL who have&#xD;
           measurable disease following previous therapy for CLL. Patients with measurable disease&#xD;
           include patients who demonstrated PD, SD, or PR following previous therapy for CLL; and&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of MEDI-538 administered by continuous IV&#xD;
           infusion for 4 weeks in this patient population;&#xD;
&#xD;
        -  Describe the pharmacokinetics (PK) of MEDI-538&#xD;
&#xD;
        -  Describe the immunogenicity (IM) of MEDI-538&#xD;
&#xD;
        -  Determine the overall response, which is defined as follows: (1) conversion from PD/SD&#xD;
           to PR/nPR/CR or conversion from PR to nPR/CR using standard NCI-WG criteria; or (2)&#xD;
           conversion from MRD positivity to MRD negativity using 4-color flow cytometry; and&#xD;
&#xD;
        -  Describe any antitumor activity (ie, time to response and duration of response) of&#xD;
           MEDI-538 in this patient population.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
        -  Determine the overall response in adult patients with CLL who have residual disease&#xD;
           following previous therapy for CLL.&#xD;
&#xD;
        -  Describe the safety of MEDI-538&#xD;
&#xD;
        -  Describe the PK of MEDI-538&#xD;
&#xD;
        -  Describe the IM of MEDI-538&#xD;
&#xD;
        -  Determine the time to MRD relapse&#xD;
&#xD;
        -  Determine the antitumor activity (ie, time to response, duration of response, and time&#xD;
           to progression [TTP]) of MEDI-538 in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Replacing this trial with a new trial.&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the Phase 1 part of the study are to evaluate the safety, tolerability, and MTD of MEDI-538 by continuous IV infusion for 4 weeks in adult patients with CLL who have measurable disease following previous therapy for CLL.</measure>
    <time_frame>30 days after patient's final dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary objective of the Phase 2 part of the study is to determine the overall response in adult patients with CLL who have residual disease following previous therapy for CLL.</measure>
    <time_frame>30 days after patient's final dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome of the Phase 1 part of the study include measurement of the PK, IM, and antitumor activity of MEDI-538 in this patient population.</measure>
    <time_frame>30 days after patient's final dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of the Phase 2 part of the study include safety, measurement of the PK, IM, and antitumor activity of MEDI-538 in this patient population.</measure>
    <time_frame>30 days after patient's final dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men or women at least 18 years of age;&#xD;
&#xD;
          -  Written informed consent and Heath Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization (applies to covered entities in the USA only) obtained from the&#xD;
             patient prior to performing any study-related procedures, including screening visits;&#xD;
&#xD;
          -  Previous confirmation of B-cell CLL with a characteristic immunophenotype by flow&#xD;
             cytometry;&#xD;
&#xD;
          -  MRD positivity, determined by 4-color flow cytometry of bone marrow or peripheral&#xD;
             blood in all patients following previous therapy for CLL;&#xD;
&#xD;
          -  Measurable and/or residual disease following previous therapy for CLL as follows:&#xD;
&#xD;
               1. Measurable disease, as determined by NCI-WG criteria, following standard&#xD;
                  first-line or salvage therapy; this includes patients with PD, SD, or PR (Phase 1&#xD;
                  only);&#xD;
&#xD;
               2. Residual disease as determined by measurable disease (ie, PD, SD, or PR) or by&#xD;
                  MRD positivity, determined by 4-color flow cytometry of bone marrow and/or&#xD;
                  peripheral blood in patients with CR or nPR (Phase 2 only);&#xD;
&#xD;
          -  Time from completing last therapy for CLL is ≥ 3 months but ≤ 1 year;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;&#xD;
&#xD;
          -  Presence of live-in companion (relative or friend) who agrees to NOT leave the patient&#xD;
             unattended for &gt; 8 hours per day;&#xD;
&#xD;
          -  Patient agrees to refrain from engaging in hazardous occupations or activities&#xD;
             requiring complete mental alertness such as operating machinery or driving a motor&#xD;
             vehicle;&#xD;
&#xD;
          -  Females, unless surgically sterile or at least 1 year post-menopausal, must use an&#xD;
             effective method of avoiding pregnancy (including oral, transdermal, or implanted&#xD;
             contraceptives, intrauterine device, female condom with spermicide, diaphragm with&#xD;
             spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual&#xD;
             partner or sterile sexual partner) for 21 days prior to the first dose of MEDI-538,&#xD;
             and must agree to continue using such precautions through 3 months after the last dose&#xD;
             of MEDI-538. Cessation of birth control after this point should be discussed with a&#xD;
             responsible physician. Males, unless surgically sterile, must likewise use an&#xD;
             effective method of birth control (condom with spermicide) and must agree to continue&#xD;
             using such precautions through 3 months after the last dose of MEDI-538;&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL and platelets &gt; 75.0 x 109/L;&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN; aspartate transaminase (AST), alanine transaminase (ALT),&#xD;
             amylase and lipase ≤ 2 x ULN;&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x ULN and creatinine clearance ≥ 50 mL/min;&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1.0 × 109/L; and&#xD;
&#xD;
          -  For patients who have received previous treatment with alemtuzumab, CD4 counts must be&#xD;
             &gt; 200 cells/μL with a negative status for cytomegalovirus (CMV) antigen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of MEDI-538 in any previous clinical study;&#xD;
&#xD;
          -  History of allergy or reaction to any component of the MEDI-538 formulation;&#xD;
&#xD;
          -  History of malignancy other than CLL within 5 years prior to study entry, with the&#xD;
             exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
             successfully treated with curative therapy;&#xD;
&#xD;
          -  Fludarabine-refractory CLL, defined as failure to achieve a PR or CR/nPR to at least&#xD;
             one fludarabine-containing regimen, disease progression while on fludarabine&#xD;
             treatment, or disease progression in responders within 6 months of last dose of&#xD;
             fludarabine;&#xD;
&#xD;
          -  Known or suspected CNS involvement;&#xD;
&#xD;
          -  Clinical history of significant CNS pathology, eg, uncontrolled headaches, multiple&#xD;
             occurrences of confusion, dementia, multiple previous infarcts, or major brain&#xD;
             surgery;&#xD;
&#xD;
          -  Active infection or known bacteremia. Patients with documented evidence of culture&#xD;
             positive sepsis or active infection requiring IV antibiotic therapy must complete a&#xD;
             full course of antibiotic treatment with no clinical or laboratory evidence of&#xD;
             bacterial infection at least 2 weeks prior to starting therapy with MEDI-538.&#xD;
&#xD;
          -  Vaccination (either preventive or therapeutic for infectious disease or cancer) within&#xD;
             2 weeks prior to initiation of MEDI-538;&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV-1 or HIV-2), chronic infection with&#xD;
             hepatitis B or C, or acute infection with hepatitis A;&#xD;
&#xD;
          -  History of serious, chronic autoimmune disease, eg, rheumatoid arthritis, systemic&#xD;
             lupus erythematosus, and multiple sclerosis;&#xD;
&#xD;
          -  Elective surgery planned during the study period through 30 days after discontinuation&#xD;
             of MEDI-538;&#xD;
&#xD;
          -  Autologous stem cell transplantation within 26 weeks prior to study entry;&#xD;
&#xD;
          -  Allogenic stem cell transplantation or any other solid organ transplant;&#xD;
&#xD;
          -  Regular dose of systemic corticosteroids during the 4 weeks prior to initiation of&#xD;
             MEDI-538 or anticipated need of corticosteroids exceeding prednisone 20 mg/day or&#xD;
             equivalent during the trial, or any other systemic immunosuppressive therapy within 4&#xD;
             weeks prior to study entry;&#xD;
&#xD;
          -  Any contraindication to chronic anticoagulation with low-molecular weight heparin&#xD;
             (LMWH);&#xD;
&#xD;
          -  Inability for safe placement and prolonged use (at least 4 weeks) of a central venous&#xD;
             catheter;&#xD;
&#xD;
          -  Contraindication to any of the protocol-specified concomitant medications&#xD;
             (methylprednisolone, antacids, or antihistamines) during this study;&#xD;
&#xD;
          -  Presence of known human anti-murine antibodies or hypersensitivity to immunoglobulins;&#xD;
&#xD;
          -  Pregnancy (females of childbearing potential must have a negative urine pregnancy test&#xD;
             on the day of the first dose of MEDI-538, prior to dosing) or nursing;&#xD;
&#xD;
          -  Evidence of any uncontrolled systemic disease (other than CLL), including autoimmune&#xD;
             hemolytic anemia;&#xD;
&#xD;
          -  Any finding upon physical examination or history of any disease or behavior that, in&#xD;
             the opinion of the investigator or medical monitor, may compromise the safety of the&#xD;
             patient in the study or confound the analysis of the study; or&#xD;
&#xD;
          -  Inability to meet social environment requirements for outpatient therapy (see Section&#xD;
             3.3.4.2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Kaucic, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>September 4, 2008</last_update_submitted>
  <last_update_submitted_qc>September 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karen Kaucic, MD</name_title>
    <organization>MedImmune</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

